IBM Watson Health is tapering off its Drug Discovery program, which uses "AI" software to help companies develop new pharmaceuticals, blaming poor sales. IBM spokesperson Ed Barbini told The Register: "We are not discontinuing our Watson for Drug Discovery offering, and we remain committed to its continued success for our clients currently using the technology. We are focusing our resources within Watson Health to double down on the adjacent field of clinical development where we see an even greater market need for our data and AI capabilities." In other words, it appears the product won't be sold to any new customers, however, organizations that want to continue using the system will still be supported. When we pressed Big Blue's spinners to clarify this, they tried to downplay the situation using these presumably Watson neural-network-generated words: The offering is staying on the market, and we'll work with clients who want to team with IBM in this area.
Apr-19-2019, 02:16:54 GMT